Principal Financial Group Inc. Has $23.87 Million Stake in ADMA Biologics, Inc. (NASDAQ:ADMA)

Principal Financial Group Inc. increased its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 785.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,194,221 shares of the biotechnology company's stock after acquiring an additional 1,059,394 shares during the quarter. Principal Financial Group Inc. owned about 0.52% of ADMA Biologics worth $23,872,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Sei Investments Co. grew its holdings in shares of ADMA Biologics by 176.0% during the 1st quarter. Sei Investments Co. now owns 393,481 shares of the biotechnology company's stock worth $2,597,000 after purchasing an additional 250,925 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in ADMA Biologics by 90.7% in the 1st quarter. Russell Investments Group Ltd. now owns 1,169,207 shares of the biotechnology company's stock valued at $7,717,000 after buying an additional 556,175 shares during the period. ProShare Advisors LLC increased its holdings in ADMA Biologics by 9.2% in the 1st quarter. ProShare Advisors LLC now owns 54,293 shares of the biotechnology company's stock valued at $358,000 after buying an additional 4,570 shares during the period. Hillsdale Investment Management Inc. raised its stake in shares of ADMA Biologics by 41,893.3% in the 1st quarter. Hillsdale Investment Management Inc. now owns 629,900 shares of the biotechnology company's stock valued at $4,157,000 after buying an additional 628,400 shares in the last quarter. Finally, CANADA LIFE ASSURANCE Co lifted its holdings in shares of ADMA Biologics by 114.3% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 54,049 shares of the biotechnology company's stock worth $357,000 after acquiring an additional 28,832 shares during the period. Institutional investors own 75.68% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have commented on the stock. Raymond James raised their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a "strong-buy" rating in a research note on Friday, November 8th. HC Wainwright raised their target price on ADMA Biologics from $18.00 to $26.00 and gave the stock a "buy" rating in a research report on Friday, November 8th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $20.00 price target on shares of ADMA Biologics in a research report on Friday, September 20th.

ADMA Biologics Price Performance

Shares of ADMA stock traded down $0.89 during trading hours on Thursday, hitting $20.58. 1,797,412 shares of the company's stock were exchanged, compared to its average volume of 3,660,826. ADMA Biologics, Inc. has a 52 week low of $3.60 and a 52 week high of $23.64. The stock has a market cap of $4.80 billion, a price-to-earnings ratio of 73.79 and a beta of 0.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The stock's 50-day moving average is $18.42 and its 200-day moving average is $14.22.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts' consensus estimates of $0.13 by $0.02. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. The firm had revenue of $119.84 million for the quarter, compared to analyst estimates of $107.25 million. During the same quarter in the prior year, the firm earned $0.01 EPS. As a group, research analysts forecast that ADMA Biologics, Inc. will post 0.52 EPS for the current year.

Insiders Place Their Bets

In other news, Director Young Kwon sold 60,000 shares of ADMA Biologics stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $18.26, for a total value of $1,095,600.00. Following the completion of the sale, the director now directly owns 241,441 shares of the company's stock, valued at approximately $4,408,712.66. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Young Kwon sold 60,000 shares of the stock in a transaction that occurred on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total value of $1,095,600.00. Following the transaction, the director now directly owns 241,441 shares in the company, valued at $4,408,712.66. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Adam S. Grossman sold 236,889 shares of the company's stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the completion of the sale, the chief executive officer now owns 2,059,726 shares of the company's stock, valued at $36,436,552.94. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 466,900 shares of company stock valued at $8,224,121. 3.70% of the stock is currently owned by corporate insiders.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.